Sooy, R. A. Han, J. -Y. Dafni, U. Cho, B. C. Yeo, C. M. and Nadal, E. Carcereny, E. de Castro, J. Sala, M. A. and Bernabe, R. Coate, L. Provencio Pulla, M. Campelo, R. Garcia and Cuffe, S. Hashemi, S. M. S. Fruh, M. Massuti, B. and Garcia-Sanchez, J. Domine, M. Majem, M. Sanchez-Torres, J. -M. Britschgi, C. Pless, M. Dimopoulou, G. and Roschitzki-Voser, H. Ruepp, B. Rosell, R. Stahel, R. A. and Peters, S. ETOP 10-16 BOOSTER Collaborators, A randomised phase II study of osimertinib and bevacizumab versus
osimertinib alone as second-line targeted treatment in advanced NSCLC
with confirmed EGFR and acquired T790M mutations: the European Thoracic
Oncology Platform (ETOP 10-16) BOOSTER trial, Annals of Oncology, (33), 181-192, 2022, Elsevier, 0923-7534, 1569-8041